Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Barter, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The realities of dyslipidaemia in metabolic syndrome and diabetes

Philip Barter

The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, Australia, 2050, p.barter{at}hri.org.au

High-density lipoprotein (HDL) removes excess cholesterol from macrophages in the artery wall, thereby reducing the rate of development of the cholesterol from macrophages in the artery wall, thereby reducing the rate of development of the atherosclerotic plaque. Other anti-atherogenic actions of HDL include preservation of endothelial function, inhibition of the recruitment of inflammatory cells to the developing plaque, antioxidant effects, and antithrombotic effects. Not surprisingly, large epidemiological cohort studies have identified low HDL-cholesterol (HDL-C) as a risk factor for coronary heart disease independently of levels of low-density lipoprotein cholesterol (LDL-C). Low HDL-C frequently occurs together with elevated triglycerides and the appearance of small, dense LDL, as a direct result of the metabolic changes associated with insulin resistance in conditions such as type 2 diabetes and the metabolic syndrome. The worldwide increase in these conditions and the associated increase in prevalence of low HDL-C have resulted in HDL being considered as a target for therapeutic intervention. Correction of low HDL-C should be an important target for therapy, especially in patients with type 2 diabetes and the metabolic syndrome.

Key Words: metabolic syndrome • type 2 diabetes • insulin resistance • HDL • dyslipidaemia • atherosclerosis.

References

  • Barter P. Metabolic abnormalities: high-density lipoproteins. Endocrinol Metab Clin North Am 2004;33:393-403.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mackness B., Hine D., Liu Y., Mastorikou M., Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 2004;318:680-3.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Clay MA, Pyle DH, Rye KA, Vadas MA, Gamble JR, Barter PJ Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. Atherosclerosis 2001;157:23-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hernandez C., Lecube A., Barbera G., Chacon P., Lima J., Simo R. Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Med Sci Monit 2003;9:CR114-CR119.[Medline] [Order article via Infotrieve]
  • Gordon T., Castelli WP, Hjortland MC, Kannel WB, Dawber TR High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wilson PW, Abbott RD, Castelli WP High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-41.[Abstract/Free Full Text]
  • Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S., Kannel WB Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8.[Abstract/Free Full Text]
  • Goldbourt U., Yaari S., Medalie JH Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13.[Abstract/Free Full Text]
  • Tanne D., Yaari S., Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic Heart Disease Study. Stroke 1997;28:83-7.[Abstract/Free Full Text]
  • Barter PJ, Rye KA High density lipoproteins and coronary heart disease. Atherosclerosis 1996;121:1-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Assmann G., Schulte H., von Eckardstein A., Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(suppl):S11-S20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70:733-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wyszynski DF, Waterworth DM, Barter PJ et al. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol 2005;95:194-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Watson KE, Horowitz BN, Matson G. Lipid abnormalities in insulin resistant states. Rev Cardiovasc Med 2003;4:228-36.[Medline] [Order article via Infotrieve]
  • Krauss RM Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504.[Abstract/Free Full Text]
  • Carr MC, Brunzell JD Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 2004;89:2601-07.[Abstract/Free Full Text]
  • Alberti KG, Zimmet PZ Definition, diagnosis and classification of diabetes mellitus and its complications. 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998;15:539-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Balkau B., Charles MA, Drivsholm T. et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-76.[Web of Science][Medline] [Order article via Infotrieve]
  • Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment for high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
  • International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available at www.idf.org, last accessed May 2005.
  • Mahley RW, Ji ZS Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999;40:1-16.[Abstract/Free Full Text]
  • Hanyu O., Miida T., Obayashi K. et al. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 2004;174: 385-90.[Web of Science][Medline] [Order article via Infotrieve]
  • Mead JR, Irvine SA, Ramji DP Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 2002;80:753-69.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • de Vries R., Borggreve SE, Dullaart RP Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin Lab 2003;49:601-13.[Medline] [Order article via Infotrieve]
  • Jeppesen J., Hollenbeck CB, Zhou MY et al. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol 1995; 15:320-4.[Abstract/Free Full Text]
  • Barter P. Metabolic abnormalities: high-density lipoproteins. Endocrinol Metab Clin North Am 2004;33:393-403.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Borggreve SE, De Vries R., Dullaart RP Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-69.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shin HK, Kim YK, Kim KY, Lee JH, Hong KW Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 2004;109:1022-8.[Abstract/Free Full Text]
  • Wilhelm MG, Cooper AD Induction of atherosclerosis by human chylomicron remnants: a hypothesis. J Atheroscler Thromb 2003;10:132-9.[Medline] [Order article via Infotrieve]
  • Floren CH, Albers JJ, Bierman EL Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cells. Biochim Biophys Acta 1981;663:336-49.[Medline] [Order article via Infotrieve]
  • Krauss RM Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504.[Abstract/Free Full Text]
  • Berneis K., Jeanneret C., Muser J., Felix B., Miserez AR Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Metabolism 2005;54: 227-34.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lemieux I., Pascot A., Couillard C. et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-84.[Abstract/Free Full Text]
  • National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final Report. National Cholesterol Education of Health. Publication No. 02-5215, 2002.
  • Seven PS, Dahlof B., Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Downs JR, Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.[Abstract/Free Full Text]
  • Chapman MJ, Assmann G., Fruchart JC, Shepherd J., Sirtori C.; European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-68.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Guyton JR Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004;5:1385-98.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 5, No. 1 suppl, S7-S11 (2005)
DOI: 10.1177/14746514050050010301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Barter, P.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?